Indeed, in EGFR/MET mice, this combination increased survival, decreased tumor burden and reduced the expression levels of all the tested key proteins implicated in lung adenocarcinoma (pEGFR, pMET, pAKT and pERK), compared with the single treatments or vehicle. The gene discussed is MET; the disease is lung adenocarcinoma.